Glioblastoma Multiforme
Conditions
Keywords
urokinase plasminogen activator receptor, positron emission tomography, glioblastoma multiforme
Brief summary
The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / MRI molecular imaging of glioblastoma.
Detailed description
68Ga-NOTA-AE105 is a radioligand targeting urokinase plasminogen activator receptor (uPAR), which is a promising imaging biomarker of tumor aggressiveness. 68Ga-NOTA-AE105 PET/MRI will be applied in patients suspected of glioblastoma multiforme. The uptake of the radioligand 68Ga-NOTA-AE105 will be compared and correlated with expression of the molecular target: uPAR using immunohistochemistry of tumor tissue samples obtained during routine stereotactic biopsies or operation. In addition, the semiquantitative uptake (standard uptake values, SUVs) of 68Ga-NOTA-AE105 in tumor tissue will be correlated with overall survival and progression free survival
Interventions
One injection of 68Ga-NOTA-AE105
DEVICEPET/MRI
Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
Sponsors
Rigshospitalet, Denmark
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients where imaging with MRI or CT is suspicious of having glioblastoma multiforme, and patients, and who is referred for stereotactic biopsy, chemotherapy or surgery * The participants must be capable of understanding and giving full informed written consent * age above 18 years
Exclusion criteria
* Pregnancy * Lactation/breast feeding * Age above 85 years old * Weight above 140 kg * Known allergy towards 68Ga-NOTA-AE105
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| uPAR PET/MRI imaging of uPAR expression | 1 hour | Standard uptake values (SUVs) of 68Ga-NOTA-AE105 evaluated on uPAR-PET/MRI scan performed within 1 hour following injection of 68Ga-NOTA-AE105, compared with immunohistochemistry of uPAR (semiquantitative) |
| uPAR PET/MRI prognostic factor for overall survival | 36 months | Patients will be followed for 36 months after uPAR/PET MRI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| uPAR PET/MRI prognostic factor for progression free survival | 36 months | Patients will be followed for 36 months |
Countries
Denmark
Contacts
Primary ContactDorthe Skovgaard, MD, PhD
Backup ContactKjaer Andreas, professor
Outcome results
None listed